冠昊生物收盘上涨1.28%，滚动市盈率127.86倍，总市值35.66亿元

Company Overview - Guanhao Biological Technology Co., Ltd. focuses on developing new products and technologies with independent intellectual property rights, aiming to enhance product quality and optimize product structure as core drivers of development [2] - The company operates in three main business segments: biomaterials, pharmaceuticals, and cells, and is committed to improving brand influence and market share [2] Financial Performance - For Q1 2025, the company reported revenue of 94.79 million yuan, a year-on-year increase of 3.67%, and a net profit of 14.87 million yuan, also up by 3.30%, with a gross profit margin of 77.05% [2] - The current stock price is 13.45 yuan, with a rolling PE ratio of 127.86, marking a new low in 30 days, and a total market capitalization of 3.566 billion yuan [1] Market Position - In the medical device industry, the average PE ratio is 49.51, and the median is 36.17, placing Guanhao Biological at the 110th position in terms of PE ratio [1][3] - As of May 9, 2025, the number of shareholders is 28,900, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]